NASDAQ · SERVICES-MEDICAL LABORATORIES · SMALL CAP
Burning Rock Biotech Limited BNR
8 fiscal years on record · CNY · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
¥539.6M
▲ 4.6% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-9.9%
Net margin · FY25
-10.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
CNY 539.6M
Revenue, FY2025 · full 8-year series below
Revenue
Net income
The company lost 10 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-9.9%
Return on equity, FY2025
ROE
Operating margin-10.2%
Net margin-10.3%
Return on assets-6.5%
Each CNY of equity lost 10 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+4.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−1.4%
+4.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
CNY 820.4M
total assets, end of FY2025
Total assetsCNY 820.4M
EquityCNY 535.3M
CashCNY 478.4M
Gross debtCNY 1.7M
Net debtCNY -476.7M
Current ratio2.99×
The company holds more cash than debt.
History
8 fiscal years
Every figure from documents filed with the SEC · CNY
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue ¥B
0.5
0.5
0.5
0.6
0.5
0.4
0.4
0.2
Operating income ¥B
−0.1
−0.4
−0.7
−1.0
−0.8
−0.4
−0.2
−0.2
EBITDA ¥B
−0.0
−0.3
−0.5
−0.9
−0.7
−0.4
−0.1
−0.1
Income tax ¥B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income ¥B
−0.1
−0.3
−0.7
−1.0
−0.8
−0.4
−0.2
−0.2
EPS, diluted ¥
·
·
·
·
·
·
·
·
Dividend / sh ¥
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
−9.9
−51.4
−67.9
−64.7
−37.3
−53.3
·
·
Shares out B
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
24 of 24
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed